RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, the pioneering leader in metabolomics-driven biomarker discovery and analysis, today announced expanded capabilities in its extensive biochemical profiling technology. The new TrueVision™ offering combines Metabolon’s powerful biochemical profiling discovery platform with complex lipid profiling. With this expansion, Metabolon can survey biological samples for over 4000 known metabolites contained in its chemical library and provide a more complete picture of lipid metabolism. The acquisition of Lipomics Technologies in 2012, now operating as a division of Metabolon with core competency in lipidomics, has enabled this unprecedented new capability.
Michael Milburn, Chief Scientific Officer at Metabolon, commented “The new TrueVision™ offering is the result of our commitment to meet our clients’ needs to find answers to their critical biological questions, advance their research, and is evidence of our dedication to continuous innovation in the field of metabolomics.”
Metabolon’s TrueVision™ platform has extensive application across the life sciences for biomarker discovery and elucidation of the effects of drugs or nutrients on metabolism. In addition, TrueVision™ provides insight into disease biology, in particular metabolic diseases, which are a family of disorders driven in large part by the subtle, long-term dysregulation of lipid metabolism. Metabolism in general and especially lipid metabolism are thought to play an important role in the development of cancer, inflammatory and central nervous system disorders which makes this comprehensive offering ideally suited for research in these therapeutic areas.
The company is also unveiling the newest version of Client Tools, a secure web portal for data delivery, interpretation and visualization of its lipidomics profiles. Client Tools includes Lipomics Surveyor® pathway maps for each analytical panel, allowing customers to view differences in lipid metabolism between treatment groups, organized by metabolic pathways. “This new software tool expands the ability of clients to visualize, present and interpret their focused lipid panel study data”, states Steve Watkins, Chief Technology Officer, Metabolon.
Metabolon, Inc. has advanced the field of metabolomics by pioneering and patenting the industry’s leading biochemical biomarker discovery and profiling platform. It has developed the technology to quickly identify and measure all of the biochemicals in a biological sample through its proprietary global processing method. Through the generation and interpretation of data, this method provides a precise understanding of disease etiology and drug action, and advances personalized medicine beyond what genomics and other approaches can promise. Metabolon’s expertise is being embraced by a wide range of pharmaceutical, biotechnology, food and agricultural companies. Metabolytics, its biomarker discovery and analysis business, has completed over 2400 client studies. As a clear demonstration of combined leadership, Metabolon and Lipomics have over 40 patents, written and contributed to well over 200 peer-reviewed journal publications and book chapters in metabolomics. Building on its expertise in biochemistry understanding, Metabolon also develops proprietary diagnostic tests to determine and track disease progression. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske at email@example.com or 919-595-2200.